NovoCure Limited Ordinary Shares (NVCR) Dividend History

Company News

• NovoCure Surpasses Q1 Expectations

  NovoCure, a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, reported strong Q1 2025 results with revenue and GAAP earnings surpassing estimates. The company saw robust patient growth and progress in clinical trials, though challenges in gross margins remain.

  The Motley Fool
• A Closer Look at 7 Analyst Recommendations For NovoCure

  7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 1 3 0 0 Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3.36% from the previous average price target of $26.17. Deciphering Analyst Ratings: An In-Depth Analysis A comprehensive examination of how financial experts perceive NovoCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Emily Bodnar HC Wainwright & Co. Maintains Neutral $22.00 $22.00 Emily Bodnar HC Wainwright & Co. Lowers Neutral $22.00 $24.00 Jason Bednar Piper Sandler Raises Overweight $28.00 $25.00 Larry Biegelsen Wells Fargo Lowers Overweight $42.00 $49.00 Emily Bodnar HC Wainwright & Co. Raises Neutral $24.00 $22.00 Jessica Fye JP Morgan Raises Neutral $17.00 $15.00 Emily Bodnar HC Wainwright & Co. Maintains Neutral $22.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, ...Full story available on Benzinga.com

  Benzinga
• NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

  NovoCure (NVCR) delivered earnings and revenue surprises of 16.28% and 5.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: LFMD
• 3M, Hawaiian Electric stocks surge, NovoCure shares plunge and other stocks on the move

  Shares of 3M, XPeng and other Chinese shares were among the most actively traded ahead of Monday's market open.

  MarketWatch

  Featured Companies: BV CRWD DJIA GDC HE KIM MMM RPT
• Tracking Baillie Gifford's 13F Portfolio - Q4 2022 Update

  Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. Click here for a detailed analysis.

  Seeking Alpha

  Featured Companies: ABCL AFRM AJG ALB ALNY AMSC AMZN APPN AXON BIRD BKNG BR CDXS CERT CHGG CHWY COUR CPNG CSGP CVNA DDOG DMRC DNA DUOL DXCM EL ELV ESTC EVER GOOG GOOGL ILMN ISRG LMND MA MBLY MCO MELI META MLM MRNA MSFT NET NFLX NVDA OSCR PCRX PTON RACE RBLX RDFN RPRX RXRX SANA SCHW SCI SG SHOP SITE SNOW SPGI SPOT STAA TDOC TEAM TMO TREE TSLA TTD TXG UPWK W WDAY WIX WRBY WSO WSO.B Z ZG ZM